Abstract
Retinopathy is a major complication of diabetes mellitus and this condition remains a leading cause of blindness in the working population of developed countries. As diabetic retinopathy progresses a range of neuroglial and microvascular abnormalities develop although it remains unclear how these pathologies relate to each other and their net contribution to retinal damage. From a haemodynamic perspective, evidence suggests that there is an early reduction in retinal perfusion before the onset of diabetic retinopathy followed by a gradual increase in blood flow as the complication progresses. The functional reduction in retinal blood flow observed during early diabetic retinopathy may be additive or synergistic to pro-inflammatory changes, leucostasis and vaso-occlusion and thus be intimately linked to the progressive ischaemic hypoxia and increased blood flow associated with later stages of the disease. In the current review a unifying framework is presented that explains how arteriolar dysfunction and haemodynamic changes may contribute to late stage microvascular pathology and vision loss in human diabetic retinopathy.
Similar content being viewed by others
Background
The worldwide incidence of diabetes is set to rise dramatically from the present incidence of 150 million to an estimated 300 million in 2025.1 Most cases will be of type II diabetes, which is closely linked to the upsurge in obesity. The complications arising from diabetes impose an ever-increasing burden on health-care authorities in both developed and developing countries. As one of the most common microvascular complications of this disease, retinopathy is set to remain a major clinical issue for the ophthalmologist. Indeed, epidemiological studies indicate that following 20 years of diabetes, nearly all patients with type I diabetes will have at least some retinopathy. Moreover, ∼80% of insulin-dependent type II diabetic patients and 50% of type II diabetic patients not requiring exogenous insulin will have retinopathy after 20 year disease duration.2 The seminal DCCT and UKPDS clinical studies in type I and type II diabetes patients, respectively, have established the relationship between time-averaged levels of glycaemia and progression of retinopathy3, 4 and these have formed a strong foundation for further research seeking to identify the cellular and molecular mechanisms underpinning retinal cell damage in diabetes.
Retinal microvascular pathology is central to understanding the nature of retinal defects during diabetes and is the focus of this review. However, our overview would be incomplete without highlighting that the purpose of these vessels is to support the metabolic demands of the inner retinal neurons and glia. Nowhere is this more apparent than in the macula, where metabolic demand is highest and the microvascular tree is at its most dense (Figure 1). Indeed, growing evidence indicates that a significant neuroglial dysfunction also occurs during diabetic retinopathy in unison with blood flow abnormalities, and before the appearance of microvascular lesions (reviewed by Antonetti et al5). In diabetic patients and short-term animal models of diabetes reversible alterations are evident in the electroretinogram (such as loss of oscillatory potentials6) together with defects in colour perception7 and impaired contrast sensitivity.8 These well-characterized electrophysiological deficits may represent a progressive ‘neuropathic’ aetiology to diabetic retinopathy.5 This is supported by detailed post-mortem studies and investigation of animal models. For example, in diabetic rodents there is a perturbation of the retinal histaminergic neurons leading to swelling of centrifugal axons9 whereas ganglion cells appear to suffer apoptotic death, even after short-term (<4 months) diabetes.10, 11 There is a thinning of the outer nuclear layer as diabetes progresses,12 loss of dopaminergic neurons,13 and ∼50% depletion of cells in the inner nuclear layer after >4 months experimental diabetes.14 Glial cells also suffer during hyperglycaemia,15 in particular the Müller macroglia which demonstrate increased expression of glial fibrillary acidic protein,16 loss of osmotic balance associated with a decrease in K+ currents,17 and concomitant synthesis/release of glutamate (as a function of disruption of the glutamate transporter18) which contributes to excitotoxicity in the retinal neuropile.19
Although the retina suffers a neuroglial pathology during diabetes, the clinically observed intraretinal microvascular changes serve as the basis for classification into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Mild non-proliferative diabetic retinopathy (often referred to as background retinopathy) and severe proliferative retinopathy actually represent the full spectrum of the same disease process. Non-proliferative diabetic retinopathy is characterized by a complex array of vasodegenerative lesions within the retinal microvascular bed, including thickening of capillary basement membranes (BMs), pericyte and vascular smooth muscle cell (VSMC) dropout, microaneurysms, and capillary occlusion and acellularity (for a review see Gardiner et al20).
Visual impairment normally occurs in the later stages of diabetic retinopathy with the development of macula oedema as a direct consequence of inner blood–retinal barrier (iBRB) breakdown. In the proliferative phase of the disease there is an abnormal growth of new blood vessels (retinal neovascularization) that give rise to sight-threatening vitreous haemorrhage and tractional retinal detachment. Macular oedema and retinal neovascularization occur as a result of increasing inner retinal ischaemia- and hypoxia-driven secretion of cytokines and growth factors, the best known being vascular endothelial growth factor (VEGF). Although sight-threatening diabetic retinopathy can be treated or contained to some extent by pan-retinal laser photocoagulation or vitreoretinal surgery this is often at the expense of functional retina and visual performance. Therefore, there is a genuine and urgent need for effective treatments for all stages of diabetic retinopathy.
Abnormal haemodynamics in diabetic retinopathy
The retinal vasculature lacks autonomic innervation and modulation of blood flow through the neuropile is dependant on local signalling mechanisms.21 As early as the 1930s it was suggested that retinal blood flow was markedly altered in diabetic patients.22 As studies progressed and technology became ever more sophisticated there were strong indications that retinal vessel calibre consistently increased during diabetes.23, 24 Direct quantification of mean circulation time during fluorescein angiography by Kohner et al25 demonstrated that that retinal blood flow was enhanced in diabetic subjects with absent or mild retinopathy, but not in those with moderate or severe diabetic retinopathy. Since these seminal studies, haemodynamic change in the diabetic retina has been the focus of considerable research although significant discrepancies exist between reported findings. This may be attributable to the variety of techniques used to measure retinal blood flow and also disparities between demographic and metabolic parameters (blood glucose, lipids, insulin, blood pressure, diabetes duration etc) of the study cohorts. As a synthesis, the majority of studies suggest that patients with short duration diabetes (<5 years) show a constriction of the major arteries and arterioles26 and retinal blood flow is decreased.27, 28 With more prolonged diabetes duration and concomitant presence of clinical retinopathy, arterial vessels begin to dilate and bulk retinal blood flow increases in proportion with the severity of retinopathy.29, 30, 31 Blood flow changes in diabetes are widely recognized but there is little direct evidence in the literature that such alterations contribute to pathology.
Retinal hypoperfusion in diabetes: links to early pathology
As outlined above, a decrease in retinal blood flow represents one of the earliest abnormalities observed in the diabetic retina. This has been confirmed in patients with type I diabetes without retinopathy using methods based on video fluorescein angiography.32, 33 Laser Doppler techniques have also revealed reduced blood flow in the large retinal vessels of diabetic patients with no retinopathy.28 In many cases, this phenomenon is linked to hyperglycaemia and haemoglobin A1c (HbA1c) with normal retinal haemodynamics occurring in well-controlled diabetic patients (HbA1c ⩽7.5%) with no or minimal retinopathy.34 It is worth noting that comparable dysregulation of retinal blood flow has also been reported in rodents up to 12 weeks after diabetes induction.35 Such animal models have formed an important basis for understanding the mechanism(s) of diabetes-mediated hypoperfusion in the retina.
Acute or chronic exposure to the diabetic milieu results in a range of biochemical and metabolic abnormalities. As a result of considerable research effort in the past 20 years, many related pathogenic mechanisms have been implicated in the progression of diabetic retinopathy. Many of these pathways are interrelated36 and it should be appreciated that hyperglycaemia can simultaneously provoke several other pathogenic pathways in retinal cells. One such mechanism is linked to increased flux through the polyol or hexosamine pathways which is associated with subsequent alterations in the redox state of pyridine nucleotides.37 Accumulation of sorbitol in retinal cells is dependant on the activity of aldose reductase and this may impinge on a range of pathways and contribute to diabetic retinopathy.38 Also de novo synthesis of diacylglycerol (DAG) leading to the over-activation of several isoforms of protein kinase C (PKC),39 excessive production of free radicals leading to oxidative stress,40, 41 changes in blood rheology and haemodynamics,42, 43 and over-activation of the renin–angiotensin system44 contribute significantly to retinopathy as diabetes progresses. Accumulation of advanced glycation end products (AGEs) and activation of receptors for AGEs are also important pathogenic mechanisms with clear links to diabetic retinopathy.36, 45
With particular links to early changes in retinal blood flow, there has been considerable emphasis placed on the activation of PKC, including several conventional and novel isoforms such as PKCα, -β, -δ, and -ɛ.46 PKC activation in diabetes may also arise through oxidative stress or increased concentrations of free fatty acids.47 The PKCβII isoform is preferentially activated in diabetic retinopathy and this can be linked to impaired retinal blood flow.46 Intravitreal injection of a DAG kinase inhibitor (that elevates total retinal DAG levels) or a PKC-activating phorbol ester serves to decrease retinal blood flow in non-diabetic rats.48 Furthermore, PKCβ knockout mice rendered diabetic exhibit no abnormalities in retinal blood flow35 whereas the specific PKCβ inhibitor ruboxistaurin (previously known as LY333531) improves retinal blood flow in diabetic animals.49 These and other related findings formed a basis for therapeutic targeting of PKCβII using the inhibitor ruboxistaurin in the hope of preventing the progression of diabetic retinopathy. This agent protected against retinal haemodynamic dysfunction in diabetic patients50 although protection was not observed for some aspects of pathology in a recent clinical trial. Ruboxistaurin did however achieve significant reduction in diabetic macular oedema.51
Another major pathway that modulates retinal vasoconstriction and decreased retinal blood flow during early diabetes is disruption of ion channel function. This dysfunction is largely concentrated at the level of the retinal arterioles as the main site for local blood flow regulation in the retina. Retinal arteriolar VSMCs express several classes of plasma membrane ion channels, including voltage-gated K+ channels, large-conductance Ca2+-activated K+ channels (BK channels), Ca2+-activated Cl− channels, and L-type Ca2+ channels which are important in controlling retinal vascular tone and blood flow.52 Within the context of diabetic retinopathy, the BK channels on retinal arteriolar VSMCs are particularly important because they show reduced Ca2+ sensitivity during early diabetes and render a sustained vasoconstrictive response when compared to non-diabetic controls.53 BK channel dysfunction during early diabetic retinopathy may represent a central mechanism underlying the hypoperfusion observed in patients and animal models.
Hypoperfusion and retinal hypoxia
From an experimental perspective, it can be surmised that deficits in retinal perfusion could impact significantly on the oxygenation of the metabolically demanding neural retina. If this association could be solidified, it would have important implications for our understanding of microvascular and neuroglial pathology during diabetic retinopathy. Deficits in oxygen delivery to the retina are observed in diabetes.54 Such hypoxia could be linked, at least in part, to blood flow abnormalities as evidenced by the finding that PO2 in diabetic cats is significantly lower than non-diabetic counterparts, even before capillary dropout is clinically observable.55 Our studies using the drug pimonidazole (which deposits as immunoreactive insoluble adducts at PO2 <10 mm Hg) has also demonstrated that hypoxia occurs in relatively short-term diabetes in mice (Figure 2). Furthermore, diabetic patients with no retinopathy or minimal lesions breathing pure oxygen show improved contrast sensitivity and colour vision suggesting that tissue hypoxia also occurs early in the course of the human disease.56, 57
Hypoperfusion and retinal capillary leucostasis
A well-described phenomenon occurring within weeks of diabetes onset is retinal capillary leucostasis, whereby blood-borne leucocytes adhere strongly to the endothelial plasma membrane and become entrapped, leading to capillary occlusion.58 Although it is difficult to determine the net contribution of leucostasis to long-term pathology, the early decrease in retinal blood flow during diabetes is likely to promote endothelial–leucocyte interactions and contribute to increased leucostasis. Under such circumstances leucocytes cannot pass unobstructed through capillary beds and they can become lodged in the narrow lumen of the capillary channels. This can result in the blockage of the affected capillary, reducing the blood flow in that area of retina and causing local tissue ischaemia.58 Leucocytes are less deformable in diabetics and this, in combination with their inappropriate adherence and inherent capacity to generate toxic superoxide radicals,59, 60 has important implications for capillary non-perfusion, endothelial cell damage, and vascular leakage in the retinal microcirculation.61
Hypoperfusion and hyperperfusion
As presented, in the early stages hypoperfusion may contribute to a low-grade, chronic inflammation of the retinal vasculature resulting in capillary dropout and the development of a progressive, irreversible ischaemic hypoxia. Tissue hypoxia causes retinal vasodilatation and enhanced retinal blood flow52 indicating that the aforementioned switch from hypoperfusion to hyperperfusion during diabetic retinopathy is probably linked to hypoxia. Indeed, it could be speculated that when retinal hypoxia reaches a certain threshold it may override the direct vasoconstrictive effects of diabetes, thereby instigating the shift to retinal hyperperfusion (Figure 3). Among the proposed mechanisms to explain retinal hypoxic vasodilatation are the release of metabolic factors from the surrounding neural tissues and the production of vasoactive agents from the endothelium.62
Can retinal hyperperfusion in diabetic retinopathy be linked to microvascular histopathology?
As diabetic retinopathy progresses there is a shift from hypoperfusion to hyperperfusion and this is associated with the transition to background and pre-proliferative diabetic retinopathy.30, 63 The particular nature of perfusion changes in patients with proliferative retinopathy tend to be associated with the microvascular pathology present in the fundus image. This is evidenced by patients with extensive retinal ischaemia which have lower volumetric flow rates than those patients that retain reasonable capillary viability.64 These findings may be reconciled on the basis that capillary density is known to be inversely correlated with vascular resistance. Some of the defined microvascular lesions of diabetic retinopathy could be linked to this shift from hypoperfusion to hyperperfusion. Indeed, the Australian Diabetes, Obesity and Lifestyle study actually indicated retinal arteriolar dilatation as a specific and effective indicator of diabetic microvascular dysfunction that could be used as a ‘pre-pathology’ marker for initiation and progression in diabetic retinopathy.65 This indicates that better-quality imaging, imaging processing, and newer techniques such as hyperspectral retinal imaging may provide tangible ways of predicting risk or monitoring progression of diabetic retinopathy in patients. We have proposed a model to explain how such alterations in retinal blood flow may lead to the initiation and progression of diabetic retinopathy (Figure 3). In particular, an emphasis has been placed on interrelationships between retinal blood flow and the evolution of the microvascular lesions that are characteristic of this complication.
Retinal capillary basement membrane thickening
Thickening of the retinal capillary BM represents an important histopathological hallmark of diabetic retinopathy (Figure 4). The expansion and change in protein composition of this specialized extracellular matrix is a reflection of the increased expression of vascular BM component proteins and a net reduction in proteolytic digestion.20 There is evidence that hyperperfusion could contribute to this lesion because increased flow, in combination with raised blood viscosity, in diabetes causes endothelial responses that increase BM thickness. Shear stress is known to regulate endothelial cell gene expression through activation of multiple intracellular signalling cascades leading to expression of BM component proteins such as collagen IV, laminin, and fibronectin.66 In fact this represents a physiological response to maintain vascular integrity by bolstering the matrix of the vessel wall. Shear stress levels are greatest in retinal arteries and arterioles67 and during diabetes BM thickening is significantly increased in capillaries that are located proximal to the arterial side of the retinal circulation.68
Loss of retinal pericytes
In the human retina, pericytes occur in a unique 1 : 1 ratio with capillary endothelium and loss of these cells during diabetic retinopathy is a characteristic pathology69 (Figure 5). Progressive pericyte demise in the retina is readily visualized by the trypsin digest technique and so-called pericyte ghosts are actually pockets of cell debris sequestered within the capillary BM. Less well recognized but equally important is the parallel demise of arterial/arteriolar VSMCs (Figure 5) in both animal models and patients.20 Focal and/or extensive loss of VSMCs has serious implications for arteriolar integrity and autoregulation of blood flow and may severely aggravate the retinal haemodynamic abnormalities observed in long-term diabetes. The mechanism underlying premature death of pericytes and VSMCs during diabetic retinopathy is the subject of significant research effort and a range of pathways have been identified such as oxidative stress, polyol pathway flux, activation of PKC, and accumulation of advanced AGEs.70 It is unlikely that pericytes/VSMC loss is directly linked to hyperperfusion; however it could be speculated that vascular BM thickening and alteration in the protein composition and charge selectivity could impact on the survival of these cells within the diabetic milieu. A two-way communication between endothelial cells and pericytes/VSMCs is vital for the maintenance of vessel integrity and function.71 Endothelial cells release vasoactive agents such as platelet-derived growth factor B for pericyte/VSMC survival,72 whereas these cells, in turn, express VEGF and angiopoeitin-1 that enhance the survival and integrity of the endothelium.71 It is likely that BM thickening serves to limit communication between endothelial cells and pericytes/VSMCs and thus contributes to accelerated vascular cell death and vessel instability in the diabetic retina. In any case, loss of pericytes and smooth muscle forms a reasonable explanation for why retinal blood flow abnormalities are irreversible in some diabetic patients with established retinopathy.73
Endothelial cell death and acellular capillary formation
Loss of capillaries is a central tenet of progressive ischaemia during diabetic retinopathy and is a universal finding in retina from long-term diabetic animal models and post-mortem specimens.20 On the trypsin digest, these acellular capillaries appear as non-perfused naked BM tubes where the endothelial cells have disappeared.20 Diabetes appears to greatly accelerate the turnover and renewal of retinal microvascular endothelial cells74 and with prolonged diabetes these cells may exhaust their replicative lifespan as they exceed the so-called Hayflick limit.75 There is evidence that bone-marrow-derived endothelial progenitor cells could contribute to a compromised endothelial monolayer because these cells are also dysfunctional in diabetes,76 as is the vessel wall they differentiate onto.77 In combination, these changes eventually lead to the formation of acellular capillaries (Figure 6).
The underlying endothelial cell insult is undoubtedly linked to previously mentioned biochemical dysfunction and evoked pathogenic pathways. However, in addition to these, hyperperfusion and resultant shear stress in the later stages of diabetic retinopathy may directly provoke retinal endothelial cell death and capillary occlusion.35 Physiological levels of shear stress are known to suppress endothelial cell apoptosis through activation of pro-survival signalling pathways such as the PI3/Akt pathway78 although pathologically enhanced shear stress can induce endothelial cell death.79
Retinal microaneurysm formation
Retinal microaneurysms have also been described in non-diabetic conditions (eg hypertension, retinal branch vein occlusions, and leukaemia) but these lesions appear with the greatest frequency in diabetic retinopathy. In fact, from the fundus image perspective, microaneurysms are the earliest clinically recognizable feature of diabetic retinopathy and they have been used as predictive markers for disease progression. Ophthalmoscopically, microaneurysms appear as small, dark red spots, approximately 10–100 μm in diameter whereas on fluorescein angiography they manifest as hyperfluorescent spots that may fade in the later phases of the angiogram. The precise nature of microaneurysms is best appreciated by trypsin digest preparation of post-mortem eyes from diabetic donors and depicts morphological forms ranging from thin walled cellular types to dense, acellular, hyalinized forms80 (Figure 6). The cellular forms can often include accumulations of monocytes and polymorphonuclear cells.80
Loss of pericytes alone cannot account for microaneurysm formation but this feature appears to be critical80 especially because these structures are often downstream from arteriolar VSMC loss and vasodilatation (Figures 5 and 6). Indeed, the role of intraluminal pressure in the pathogenesis of microaneurysms is supported by the observation that these lesions tend to occur largely on the arterial side of the capillary bed in both diabetic patients and long-term animal models such as diabetic dogs (Figure 6).20, 80 In diabetic patients, microaneurysms tend to cluster upstream of large areas of capillary non-perfusion, indicating a common link to occlusion.20 Interestingly microaneurysms fail to develop in diabetic rodents. This may be because the rodent retinal vasculature, unlike that in humans and dogs, contains precapillary sphincters81 which probably protect capillary beds from hypertensive injury.
Geographic variability exists in the distribution of acellular capillaries and microaneurysms within the diabetic retina. In both dogs and humans, capillary acellularity is significantly more prevalent within the temporal retina than in the nasal retina82 and progresses from the arterial to venous side of the retinal circulation as the disease progresses.83 Because flow rate in temporal retinal vessels is greater than that in nasal vessels84 and flow-related stress is probably enhanced in the juxta-arteriolar capillary beds, this also provides support for the key involvement of haemodynamic dysfunction in diabetic retinopathy.
Retinal blood flow and vision loss in diabetic retinopathy
Macular oedema
Fluid balance across the retinal capillary beds depends upon the hydrostatic and oncotic pressure gradients. The hydrostatic pressure gradient within capillaries serves to push fluid out of the vessel into the interstitium. As a counterbalance, the oncotic pressure gradient is formed by protein concentration in the blood column that draws fluid into the capillaries. When the hydrostatic pressure gradient and oncotic pressure gradient are in balance there is no imbalance of fluid movement between the capillaries and the tissue compartment. For the retina, this equilibrium is particularly important because there are no lymphatics present to drain excess fluid from the interstitium and it is critical to maintain fluid balance for neural health and function.
When excessive vasopermeability occurs at the macular, so-called diabetic macular oedema can precipitate serious loss of visual acuity within a short time frame. This pathology can occur quite early, but is most prevalent in the late stages of diabetic retinopathy. The Wisconsin epidemiological study demonstrated that diabetic macular oedema occurred in up to 6% of patients with mild non-proliferative retinopathy but this figure rose dramatically to 20–63% of patients with moderate to severe non-proliferative retinopathy and 70–74% of patients with proliferative retinopathy.85 In fluorescein angiograms, diabetic macular oedema can appear as focal or diffuse, with the former associated with leaking microaneurysms and the later being a consequence of wholesale breakdown of the iBRB adjacent to the macula.86 The Early Treatment Diabetic Retinopathy Study demonstrated that focal laser photocoagulation in the macula provides benefit to patients with diabetic macular oedema87 although this prevented further vision loss rather than to improve vision.
Breakdown of the iBRB can occur early after establishment of diabetes and most research focus has been placed on short-term retinopathy models in rodents where acute-phase vasopermeability is evident after only 2–3 weeks diabetes.88, 89 Various studies have shown that manipulation of adhesion molecules, pro-inflammatory cytokines, and nitric oxide can prevent this lesion within an acute time frame.88, 89 It remains uncertain how iBRB compromise early in diabetes relates to more long-term, sight-threatening macular oedema.
The precise mechanism of iBRB compromise during diabetic retinopathy remains incompletely elucidated but there are firm links with diabetes-mediated upregulation of the potent vasopermeability factor VEGF from the neural retina90 (Figure 7). VEGF modulates loss of tight junction integrity or enhanced transport mechanisms in endothelial cells in the early stages of diabetic retinopathy.91, 92 Upregulation of this growth factor occurs early in diabetes, which suggests that expression may be linked to acute hyperglycaemia, alterations in retinal blood flow, and/or enhanced pro-inflammatory processes influencing retinal capillary function.93, 94 Anti-VEGF therapy shows some potential for the treatment of diabetic patients with macular oedema.95
Abnormal retinal blood flow may contribute directly to the development of diabetic maculopathy (Figure 3). The hydrostatic pressure in the retinal capillaries is increased during long-term diabetes due to retinal arteriolar vasodilatation and increased retinal blood flow. Indeed, dilatation of the retinal arterioles has been shown to occur before the development of diabetic macular oedema96 whereas reversal of vasopermeability and oedema following pan-retinal laser photocoagulation is associated with retinal vasoconstriction.64 Supporting evidence for involvement of abnormal retinal blood flow in oedema comes from studies that indicate diffuse macular swelling is more than three times greater in diabetic patients with hypertension97 and that reducing blood pressure protects against this end point.4
Preretinal neovascularization
The proliferative diabetic retinopathy stage involves the formation of new blood vessels that develop from the venous side of the retinal circulation and penetrate the inner limiting membrane into the vitreous. Typically these new blood vessels are fragile and leaky and if left untreated can become enveloped by a thick and densely fibrous connective tissue layer. This fibrous tissue contributes to the formation of firm adhesions at the posterior hyaloid membrane and may eventually contract as it matures. Such traction can result in preretinal or vitreous haemorrhages or tractional retinal detachment leading to sudden visual loss. Proliferative retinopathy occurs in approximately 50% of patients with type I diabetes and in about 15% of patients with type II diabetes who have the disease for 25 years.98, 99
The proliferative stage of diabetic retinopathy is driven by progressive retinal ischaemia that promotes expression of hypoxia-linked angiogenic agents. An array of hypoxia-regulated cytokines and growth factors has been implicated in the pathogenesis of retinal neovascularization. Of these vasoactive agents, VEGF has received most attention and it is markedly elevated in the vitreous of patients with active proliferative retinopathy compared to those with quiescent proliferative retinopathy.100 Indeed, delivery of exogenous VEGF peptide into the vitreous of normal primate eyes can itself stimulate neovascularization.101 This and a wealth of related experimental evidence have rendered VEGF as a promising therapeutic target for proliferative diabetic retinopathy.102 Although the use of VEGF-blocking agents has shown efficacy in patients with sight-threatening proliferative retinopathy, the use of such agents is controversial as they do not address the underlying vascular insufficiency and there are appropriate concerns that such therapy could compromise retinal neuroglial and functional microvascular survival.103, 104, 105 There is a pressing need for phase III clinical trials of anti-VEGF strategies in the context of diabetic retinopathy.
Summary
Diabetic retinopathy is a multi-factorial condition arising from the complex interplay between biochemical and metabolic abnormalities occurring in all cells of the retina. Identification of a precise pathogenesis that links the progressive neuroglial and microvascular damage occurring in the diabetic retina remains a valid but somewhat elusive goal. In the current review, a unifying haemodynamic framework has been proposed that not only explains how the biphasic changes in retinal blood flow observed in diabetes may be interrelated, but also how these changes may contribute directly to the development of diabetes-related microangiopathy and vision loss (Figure 3). It is hoped that this proposal encourages future studies that seek to improve our understanding of retinal haemodynamics and its role in the pathogenesis of diabetic retinopathy. Such research would be timely, because development of new treatments for this disease has been hampered by the slow time course over which it develops. If it can be proven that haemodynamic changes are prognostic indicators for diabetic retinopathy progression, robust measures of retinal blood flow change in patients could become an important surrogate end point for clinical drug trials that may ultimately improve the prognosis for patients with this complication.
References
King H, Aubert RE, Herman WH . Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21 (9): 1414–1431.
Klein R, Klein BE, Moss SE . The Wisconsin Epidemiological Study of Diabetic Retinopathy: a review. Diabetes Metab Rev 1989; 5 (7): 559–570.
DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329 (14): 977–986.
UKPDS (UK Prospective Diabetes Study Group). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703–713.
Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55 (9): 2401–2411.
Hancock HA, Kraft TW . Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004; 45 (3): 1002–1008.
Ewing FM, Deary IJ, Strachan MW, Frier BM . Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 1998; 19 (4): 462–476.
Jackson GR, Owsley C . Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 2003; 21 (3): 709–728.
Gastinger MJ, Barber AJ, Khin SA, McRill CS, Gardner TW, Marshak DW . Abnormal centrifugal axons in streptozotocin-diabetic rat retinas. Invest Ophthalmol Vis Sci 2001; 42 (11): 2679–2685.
Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB . Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004; 45 (9): 3330–3336.
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW . Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102 (4): 783–791.
Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003; 46 (9): 1260–1268.
Nishimura C, Kuriyama K . Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes. J Neurochem 1985; 45 (2): 448–455.
Zeng XX, Ng YK, Ling EA . Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000; 17 (3): 463–471.
Agardh E, Bruun A, Agardh CD . Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes. Curr Eye Res 2001; 23 (4): 276–284.
Kusner LL, Sarthy VP, Mohr S . Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Muller cells. Invest Ophthalmol Vis Sci 2004; 45 (5): 1553–1561.
Pannicke T, Iandiev I, Wurm A, Uckermann O, vom Hagen F, Reichenbach A et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 2006; 55 (3): 633–639.
Puro DG . Diabetes-induced dysfunction of retinal Muller cells. Trans Am Ophthalmol Soc 2002; 100: 339–352.
Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47 (5): 815–820.
Gardiner TA, Archer DB, Curtis TM, Stitt AW . Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation 2007; 14 (1): 25–38.
Delaey C, Van dV . Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res 2000; 32 (6): 249–256.
Wagener HP, Story DTD, Wilder RM . Retinitis in diabetes. N Engl J Med 1934; 211: 1131–1137.
Ballantyne AJ, Loewenstein A . The pathology of diabetic retinopathy. Trans Ophthalmol Soc UK 1943; 63: 95–113.
Skovborg F, Nielsen AV, Lauritzen E, Hartkopp O . Diameters of the retinal vessels in diabetic and normal subjects. Diabetes 1969; 18 (5): 292–298.
Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt CJ . The retinal blood flow in diabetes. Diabetologia 1975; 11 (1): 27–33.
Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002; 287 (19): 2528–2533.
Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA . Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37 (5): 886–897.
Feke GT, Buzney SM, Ogasawara H, Fujio N, Goger DG, Spack NP et al. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci 1994; 35 (7): 2968–2975.
Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE . Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997; 124 (4): 433–446.
Grunwald JE, Riva CE, Baine J, Brucker AJ . Total retinal volumetric blood flow rate in diabetic patients with poor glycemic control. Invest Ophthalmol Vis Sci 1992; 33 (2): 356–363.
Patel V, Rassam S, Newsom R, Wiek J, Kohner E . Retinal blood flow in diabetic retinopathy. BMJ 1992; 305 (6855): 678–683.
Bertram B, Wolf S, Fiehofer S, Schulte K, Arend O, Reim M . Retinal circulation times in diabetes mellitus type 1. Br J Ophthalmol 1991; 75 (8): 462–465.
Bursell SE, Clermont AC, Shiba T, King GL . Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Curr Eye Res 1992; 11 (4): 287–295.
Lorenzi M, Feke GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F et al. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. Diabetologia 2008; 51 (2): 361–364.
Clermont AC, Bursell SE . Retinal blood flow in diabetes. Microcirculation 2007; 14 (1): 49–61.
Stitt AW, Curtis TM . Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005; 57 (Suppl): 156–168.
Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR et al. Prevention of hemodynamlemma and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989; 38 (10): 1258–1270.
Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M . A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006; 55 (10): 2757–2762.
Curtis TM, Scholfield CN . The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20 (1): 28–43.
Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44 (9): 1102–1110.
Kowluru RA, Atasi L, Ho YS . Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006; 47 (4): 1594–1599.
Tooke J . Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 2000; 14 (4): 197–200.
Schmetterer L, Wolzt M . Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999; 42 (4): 387–405.
Miyata T, van Ypersele de Strihou C . Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003; 419 (1): 50–54.
Bhatwadekar A, Stitt AW . AGEs and RAGE inhibitors in the treatment of diabetic retinopathy. Expert Rev Ophthalmol 2007; 2 (1): 105–120.
Koya D, King GL . Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47 (6): 859–866.
Curtis TM, Scholfield CN . The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20 (1): 28–43.
Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997; 38 (13): 2711–2720.
Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272 (5262): 728–731.
Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE . Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47 (1): 86–92.
Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X et al. PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009; 50 (1): 1–4.
Scholfield CN, McGeown JG, Curtis TM . Cellular physiology of retinal and choroidal arteriolar smooth muscle cells. Microcirculation 2007; 14 (1): 11–24.
McGahon MK, Dash DP, Arora A, Wall N, Dawicki J, Simpson DA et al. Diabetes downregulates large-conductance Ca2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle. Circ Res 2007 100 (5): 703–711.
Alder VA, Su EN, Yu DY, Cringle SJ, Yu PK . Diabetic retinopathy: early functional changes. Clin Exp Pharmacol Physiol 1997; 24 (9–10): 785–788.
Linsenmeier RA, Braun RD, McRipley MA, Padnick LB, Ahmed J, Hatchell DL et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 1998; 39 (9): 1647–1657.
Dean FM, Arden GB, Dornhorst A . Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent diabetic subjects. Br J Ophthalmol 1997; 81 (1): 27–30.
Harris A, Arend O, Danis RP, Evans D, Wolf S, Martin BJ . Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996; 80 (3): 209–213.
Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP . Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158 (1): 147–152.
Nishiwaki H, Ogura Y, Kimura H, Kiryu J, Honda Y . Quantitative evaluation of leukocyte dynamics in retinal microcirculation. Invest Ophthalmol Vis Sci 1995; 36 (1): 123–130.
Kunt T, Forst T, Fruh B, Flohr T, Schneider S, Harzer O et al. Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Exp Clin Endocrinol Diabetes 1999; 107 (4): 252–256.
Schroder S, Palinski W, Schmid-Schonbein GW . Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139 (1): 81–100.
Delaey C, Boussery K, Van de Voorde J . A retinal-derived relaxing factor mediates the hypoxic vasodilation of retinal arteries. Invest Ophthalmol Vis Sci 2000; 41 (11): 3555–3560.
Yoshida A, Feke GT, Morales-Stoppello J, Collas GD, Goger DG, McMeel JW . Retinal blood flow alterations during progression of diabetic retinopathy. Arch Ophthalmol 1983; 101 (2): 225–227.
Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I . Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115 (1): 64–67.
Rogers SL, Tikellis G, Cheung N, Tapp R, Shaw J, Zimmet PZ et al. Retinal arteriolar caliber predicts incident retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care 2008; 31 (4): 761–763.
Thoumine O, Nerem RM, Girard PR . Changes in organization and composition of the extracellular matrix underlying cultured endothelial cells exposed to laminar steady shear stress. Lab Invest 1995; 73 (4): 565–576.
Nagaoka T, Yoshida A . Noninvasive evaluation of wall shear stress on retinal microcirculation in humans. Invest Ophthalmol Vis Sci 2006; 47 (3): 1113–1119.
Stitt AW, Anderson HR, Gardiner TA, Archer DB . Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol 1994; 78 (2): 133–137.
Cogan DG, Toussaint D, Kuwabara T . Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366–378.
Stitt AW, Jenkins AJ, Cooper ME . Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002; 11 (9): 1205–1223.
Armulik A, Abramsson A, Betsholtz C . Endothelial/pericyte interactions. Circ Res 2005; 97 (6): 512–523.
Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003; 17 (15): 1835–1840.
Grunwald JE, Brucker AJ, Schwartz SS, Braunstein SN, Baker L, Petrig BL et al. Diabetic glycemic control and retinal blood flow. Diabetes 1990; 39 (5): 602–607.
Sharma NK, Gardiner TA, Archer DB . A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Ophthalmol 1985; 100 (1): 51–60.
Linskens MH, Harley CB, West MD, Campisi J, Hayflick L . Replicative senescence and cell death. Science 1995; 267 (5194): 17.
Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007; 56 (4): 960–967.
Bhatwadekar AD, Glenn JV, Li G, Curtis TM, Gardiner TA, Stitt AW . Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Investig Ophthalmol Vis Sci 2008; 49 (3): 1232–1241.
Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM . Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 1998; 83 (3): 334–341.
Li M, Zhao MQ, Kumar Durairajan SS, Xie LX, Zhang HX, Kum WF et al. Protective effect of tetramethylpyrazine and salvianolic acid B on apoptosis of rat cerebral microvascular endothelial cell under high shear stress. Clin Hemorheol Microcirc 2008; 38 (3): 177–187.
Stitt AW, Gardiner TA, Archer DB . Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995; 79 (4): 362–367.
Pannarale L, Onori P, Ripani M, Gaudio E . Precapillary patterns and perivascular cells in the retinal microvasculature. A scanning electron microscope study. J Anat 1996; 188 (Part 3): 693–703.
Kern TS, Engerman RL . Vascular lesions in diabetes are distributed non-uniformly within the retina. Exp Eye Res 1995; 60 (5): 545–549.
Ashton N . Arteriolar involvement in diabetic retinopathy. Br J Ophthalmol 1953; 37 (5): 282–292.
Rassam SM, Patel V, Chen HC, Kohner EM . Regional retinal blood flow and vascular autoregulation. Eye 1996; 10 (Part 3): 331–337.
Klein R, Klein BE, Moss SE, Cruickshanks KJ . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102 (1): 7–16.
Girach A, Lund-Andersen H . Diabetic macular oedema: a clinical overview. Int J Clin Pract 2007; 61 (1): 88–97.
ETDRS. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98 (5 Suppl): 766–785.
El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB . Experimental diabetes causes breakdown of the blood–retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162 (6): 1995–2004.
Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K et al. VEGF-initiated blood–retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42 (10): 2408–2413.
Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW . Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38 (1): 36–47.
Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW . Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274 (33): 23463–23467.
Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW . Inhibition of advanced glycation and absence of galectin-3 prevent blood–retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007; 2007: 51837.
Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16 (3): 438–440.
Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160 (2): 501–509.
Cunningham Jr ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112 (10): 1747–1757.
Kristinsson JK, Gottfredsdottir MS, Stefansson E . Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 1997; 81 (4): 274–278.
Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW . Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77 (2): 170–175.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102 (4): 527–532.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102 (4): 520–526.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331 (22): 1480–1487.
Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103 (11): 1820–1828.
Spaide RF, Fisher YL . Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26 (3): 275–278.
Benjamin LE, Hemo I, Keshet E . A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125 (9): 1591–1598.
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171 (1): 53–67.
Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE 2008; 3 (11): e3554.
Acknowledgements
We thank The Juvenile Diabetes Research Foundation (JDRF) who funded this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Curtis, T., Gardiner, T. & Stitt, A. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. Eye 23, 1496–1508 (2009). https://doi.org/10.1038/eye.2009.108
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2009.108
Keywords
This article is cited by
-
Proliferative diabetic retinopathy and diabetic macular edema are two factors that increase macrophage-like cell density characterized by en face optical coherence tomography
BMC Ophthalmology (2023)
-
Risk of cataract and glaucoma among older persons with diabetes in India: a cross-sectional study based on LASI, Wave-1
Scientific Reports (2023)
-
Perspectives of diabetic retinopathy—challenges and opportunities
Eye (2023)
-
Homeostasis and dyshomeostasis of the retina
Current Medicine (2023)
-
Peripapillary circulatory dysfunction precedes structural loss in treatment-naive diabetic retinopathy
Graefe's Archive for Clinical and Experimental Ophthalmology (2023)